Initial Public Offering

Healthcare
Initial Public Offering

Summary

Baird served as a co-manager on this offering

About

Twist Bioscience Corporation (“Twist” or the “Company”) (NASDAQ-GS: TWST) recently completed an initial public offering of 5,750,000 shares of its common stock, including the exercise in full of the underwriters' option to purchase 750,000 additional shares of common stock, at a public offering price of $14.00 per share. The gross proceeds to Twist, before deducting underwriting discounts, commissions and offering expenses, were approximately $80.5 million. Twist intends to use the proceeds from this offering to improve and update the Company’s platform and core technologies, expand its sales and marketing capabilities in the United States and in other geographies, including China, develop and expand into the biologics drug discovery and DNA data storage markets, and for working capital and general corporate purposes.

Twist is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the Company’s platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist leverages its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next generation sample (NGS) preparation, and antibody libraries for drug discovery and development. The Company is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research. The Company is headquartered in San Francisco, California.
CONTACT US TO LEARN MORE
Healthcare
Initial Public Offering
Date
October 2018
Company
Twist Bioscience Corporation
Transaction
M&A
Sectors
Healthcare
Target Location
North America

Share